These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1193 related articles for article (PubMed ID: 19637364)

  • 1. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
    Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
    Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
    J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
    Kim JI; Suh JT; Choi KU; Kang HJ; Shin DH; Lee IS; Moon TY; Kim WT
    Hum Pathol; 2009 Jul; 40(7):934-41. PubMed ID: 19356788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
    Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
    J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases.
    Nagasaka T; Sharp GB; Notohara K; Kambara T; Sasamoto H; Isozaki H; MacPhee DG; Jass JR; Tanaka N; Matsubara N
    Clin Cancer Res; 2003 Nov; 9(14):5306-12. PubMed ID: 14614014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
    Nakagawa T; Ido K; Sakuma T; Takeuchi H; Sato K; Kubota T
    Neuropathology; 2009 Aug; 29(4):379-88. PubMed ID: 19019175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter hypermethylation in a series of 104 glioblastomas.
    Mellai M; Caldera V; Annovazzi L; Chiò A; Lanotte M; Cassoni P; Finocchiaro G; Schiffer D
    Cancer Genomics Proteomics; 2009; 6(4):219-27. PubMed ID: 19656999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of O6-methylguanine DNA methyltransferase in the absence of promoter hypermethylation in hepatocellular carcinomas from Australia and South Africa.
    Herath NI; Walsh MD; Kew M; Smith JL; Jass JR; Young J; Leggett BA; Macdonald GA
    Oncol Rep; 2007 Apr; 17(4):817-22. PubMed ID: 17342321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.